The drug works.
The behavior fails.
We fix that.
Ew2health gives medical weight-loss clinics a predictive view of GLP-1 adherence, dropout risk, and treatment effectiveness — so you can guide patients, not just measure them, toward lasting change.
GLP-1 DROPOUT
65% / year
AVG. WEIGHT LOSS ON GLP-1
15–20%
REGAIN AFTER STOPPING
~⅔ in 1 yr
Adherence forecast
On track · 14 days
The Problem
The leaky bucket.
GLP-1 prescriptions are growing. Long-term outcomes are not following.
Patients disengage — not because they don't care, but because the system feels unsafe and unsupported. Clinics absorb the cost: lost adherence, lost retention, lost lifetime value.
18-23%
annual growth of GLP-1 prescriptions
65%
loss of GLP-1 treatment revenues
45%
loss of GLP-1 patient lifetime value (LTV)
The Solution
Ew2health is the predictive behavioral intelligence infrastructure for obesity care.
We monitor behavior — not just biomarkers — to forecast where a patient is headed, up to 15 days ahead. Our patented Predictive Behavioral Analytics, paired with a 3D biomarker model, gives medical weight-loss clinics a predictive view of adherence, dropout risk, and treatment effectiveness — turning GLP-1 care from reactive to proactive.
The 3D biomarker model
Ew2health PBA
Weight
High-frequency self-monitoring, 3–4× per week, interpreted by our patented PBA.
with Roche
Glucose
Continuous glucose variability as a real-time metabolic signal.
with Garmin
Cardiorespiratory fitness
VO₂max and activity load — the strongest long-term outcome predictor.
The shift we stand for
A new operating model for obesity care.
What makes us unique
The only company that turns behavior into a predictive signal.
Biomarkers tell clinics where the patient is. Behavior tells clinicians where a patient is headed. We forecast the trajectory.
01
We monitor behavior, not just biomarkers — and that is what makes us predictive.
Our patented PBA (US Patent 11,633,160) reads how a person is living and forecasts their weight trajectory up to 15 days ahead.
02
We encourage frequent self-monitoring — building a unique, high-frequency dataset.
Patients self-monitor 3–4× per week without judgment, producing a longitudinal dataset competitors can't replicate.
03
We integrate into the workflow of medical weight-loss clinics — improving outcomes.
We catch disengagement before drop-out — the industry's biggest revenue leak — and enable personalized titration between appointments.
04
We are building a 3D biomarker architecture — the biological context behind the behavior.
Weight · Roche CGM glucose · Garmin VO₂max, on the Mayo Clinic Platform — helping clinicians tell behavior problems from biology ones.
Coming soonWho We Serve
From clinics today to the infrastructure of metabolic care.
Ew2health serves the operators driving obesity care today, while building the behavioral intelligence layer the broader ecosystem will rely on tomorrow.
FOUNDATION
Medical weight-loss programs & clinics
GLP-1 clinics in the Netherlands, Brazil, and expanding to the US.
EXPANSION
Telemedicine & virtual clinic chains
Licensing the platform to scale behavioral intelligence across networks.
PLATFORM PARTNERSHIPS
Pharma · Medtech · Wearables
Intelligence layer for GLP-1. The clinical-grade solution for continuous monitoring.
The Patient Experience
Meet Sinque — the health compass of the platform.
Sinque empowers individuals to take consistent, meaningful action toward better health. It provides medically accurate and accessible insights, so users can learn what they need to do to improve their wellbeing over time.
- A trusted, science-based tool/technology
- Transforms complex health data into clear guidance
- Motivates users to build sustainable habits
Trusted infrastructure. Validated science.
Built with the leaders in metabolic health.
US Patent 11,633,160 — Predictive Behavioral Analytics
Ew2health is the behavioral intelligence infrastructure for modern obesity care
Investor information →